UK markets closed

Protagenic Therapeutics, Inc. (PTIX)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
1.7500-0.0200 (-1.13%)
At close: 04:00PM EDT

Protagenic Therapeutics, Inc.

149 Fifth Avenue
Suite 500
New York, NY 10010
United States
212 994 8200
https://www.protagenic.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees

Key executives

NameTitlePayExercisedYear born
Dr. Garo H. Armen Ph.D.Co-Founder & Executive Chairman of the BoardN/AN/A1953
Dr. Alexander Kenneth Arrow C.F.A., M.D.CFO & Secretary150kN/A1971
Dr. Andrew SleeChief Operating OfficerN/AN/A1950
Dr. Robert Benjamin Stein M.D., Ph.D.Chief Medical Officer & DirectorN/AN/A1951
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

Corporate governance

Protagenic Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.